Invenra is partnering with Astellas Pharma, a global pharmaceutical company with a vision to turn innovative science into value for patients, the company announced today.

According to a release, the agreement will leverage Invenra’s B-Body bispecific antibody platform to support Astellas’ focused research and development initiatives.

“We are honored to partner with the Astellas team, one of the world’s foremost developers of therapeutics,” Invenra CEO Dr. Roland Green said in a statement. “We are excited by the potential of this partnership to yield profound benefits to patients in need.”

Astellas will have access to Invenra’s B-Body technology and at the end of the research, it will have the option to negotiate future licenses.